Skip to main content
Acta Crystallographica Section F: Structural Biology and Crystallization Communications logoLink to Acta Crystallographica Section F: Structural Biology and Crystallization Communications
. 2012 Oct 30;68(Pt 11):1329–1332. doi: 10.1107/S1744309112038523

Purification, crystallization and preliminary X-ray diffraction analysis of an acidic phospholipase A2 with vasoconstrictor activity from Agkistrodon halys pallas venom

Zhisong Zou a,b, Fuxing Zeng a,b, Lu Zhang a,b, Liwen Niu a,b, Maikun Teng a,b,*, Xu Li a,b,*
PMCID: PMC3515374  PMID: 23143242

A vasoconstrictor PLA2 was purified from Agkistrodon halys pallas venom and the preliminary X-ray diffraction analysis had been described.

Keywords: phospholipases A2, Agkistrodon halys pallas, snake venoms

Abstract

Phospholipases A2 (PLA2s) are the major component of snake venoms and exert a variety of relevant toxic actions such as neurotoxicity and myotoxicity, amongst others. An acidic PLA2, here named AhV_aPA, was purified from Agkistrodon halys pallas venom by means of a three-step chromatographic procedure. AhV_aPA migrated as a single band on SDS–PAGE gels, with a molecular weight of about 14 kDa. Like other acidic aPLA2s, AhV_aPA has high enzymatic activity. Tension measurements of mouse thoracic aortic rings remarkably indicated that AhV_aPA could induce a further contractile response on the 60 mM K+-induced contraction, with an EC50 of 369 nmol l−1. Rod-shaped crystals were obtained by the hanging-drop vapour-diffusion method and diffracted to a resolution limit of 2.30 Å. The crystals belonged to space group P222, with unit-cell parameters a = 44.27, b = 68.39, c = 81.54 Å.

1. Introduction  

Phospholipases A2 (PLA2s; EC 3.1.1.4) catalyze the hydrolysis of glycerophospholipids at the sn-2 position, releasing lysophospho­lipids and fatty acids (Kini, 2003). The PLA2 superfamily has been divided into 15 groups and many subgroups, and includes six distinct types of enzymes, namely the secreted PLA2s (sPLA2s), the cytosolic PLA2s (cPLA2s), the Ca2+-independent PLA2s (iPLA2)s, the platelet-activating factor acetyl­hydrolases (PAF-AHs), lysosomal PLA2 and a recently identified adipose-specific PLA2 (Duncan et al., 2008). Snake venoms are one of the most abundant sources of sPLA2s (dos Santos et al., 2011).

Snake-venom PLA2s display a wide range of isoelectric points from acidic to highly basic. These isoforms differ significantly in catalytic properties and pharmacological activities. The acidic PLA2s with an Asp residue at position 49 show the highest in vitro catalytic activity towards conventional substrates; they do not exhibit neurotoxic activity, but rather antiplatelet aggregation, antibacterial, pro­inflammatory and myotoxic activities (Fuly et al., 2000; Fernández et al., 2010; Nunes et al., 2011; Saikia et al., 2011; Teixeira et al., 2011). Nevertheless, the basic isoforms appear to have acquired the highest toxicity, especially in the case of neurotoxic and myotoxic enzymes (Ponce-Soto et al., 2009). In addition to the classic pharmacological activities, recent studies showed that atratoxin, an acidic PLA2 from Naja atra venom, is able to inhibit A-type K+ currents in dissociated rat DRG neurons (Hu et al., 2008).

In this work, we report the crystallization and preliminary X-ray diffraction analysis of AhV_aPA isolated from the venom of Agkistrodon halys pallas, which presents high catalytic activity towards egg-yolk phospholipids as the substrate. The present study shows that AhV_aPA also has a vasoconstrictor effect on mouse thoracic aortic rings. This indicates that AhV_aPA may have effects on the ion channels or receptors in the plasma membrane of vascular smooth-muscle cells.

2. Materials and methods  

2.1. Purification  

AhV_aPA was purified from lyophilized crude venom of A. halys pallas (Tunxi Snakebite Institute, Anhui, People’s Republic of China) using the following three-step chromatographic procedure at 287 K (Fig. 1). Lyophilized A. halys pallas venom (1.0 g) was dissolved in 25 ml buffer A (20 mM NaH2PO4/Na2HPO4 pH 6.0) and centrifuged at 18 800g for 15 min to remove the insoluble portion. The supernatant was applied at a rate of 1 ml min−1 onto a CM-Sepharose Fast Flow column (GE Healthcare) pre-equilibrated with the same buffer. After the unbound fractions had been washed out, a gradient of 0–­0.4 M NaCl in buffer B (20 mM NaH2PO4/Na2HPO4 pH 8.0) was used. The unbound fractions in peak 1 were collected, dialyzed against buffer C (50 mM Tris–HCl pH 8.0) and applied onto a DEAE-Sepharose Fast Flow column (GE Healthcare) pre-equilibrated with buffer C. The column was eluted at a flow rate of 1 ml min−1 using an NaCl gradient (0–0.4 M). The fractions corresponding to peak 4 were collected and purified on a Superdex 75 column (GE Healthcare) pre-equilibrated with buffer D (20 mM Tris–HCl pH 8.0, 200 mM NaCl) and eluted at a flow rate of 1 ml min−1. Fractions containing AhV_aPA (peak 4) were collected and dialyzed against deionized water to remove salt. The purity of the protein was identified by SDS–PAGE. Protein concentration was determined using the BCA Protein Assay (Thermo Scientific).

Figure 1.

Figure 1

The purification of AhV_aPA using a three-step chromatographic protocol. (a) CM-Sepharose cation-exchange chromatography. (b) DEAE-Sepharose anion-exchange chromatography. (c) Superdex 75 molecular-exclusion chromatography. The inset shows the SDS–PAGE gel image. Lane P, AhV_aPA; lane M, molecular-mass markers (labelled in kDa).

2.2. Crystallization  

AhV_aPA was concentrated to 25 mg ml−1 in buffer E (5 mM Tris pH 7.5, 50 mM NaCl). Crystallization experiments were performed at 287 K by the hanging-drop vapour-diffusion method with drops consisting of 1 µl protein solution and 1 µl reservoir solution, using Hampton Research crystallization screens to screen for initial crystallization conditions. Microcrystals were observed within one week using a precipitant solution consisting of 20% PEG 4000, 0.1 M Tris pH 8.0. Subsequent screening was performed by varying the pH and the PEG 4000 concentration. After optimization, crystals of high quality were obtained using 18% PEG 4000, 0.1 M Tris pH 8.0 and were used for data collection (Fig. 2).

Figure 2.

Figure 2

Crystals of AhV_aPA.

2.3. X-ray diffraction analysis  

All diffraction data were obtained from a crystal cryoprotected in 18% PEG 4000, 0.1 M Tris pH 8.0, 25%(v/v) glycerol. The crystal was directly flash-cooled in a stream of cold nitrogen gas at 100 K. A set of diffraction data was collected at 100 K on beamline BL17U at Shanghai Synchrotron Radiation Facility (SSRF) and was subsequently processed to 2.30 Å resolution using HKL-2000 (Otwinowski & Minor, 1997). The cutoff at 2.30 Å resolution was chosen because in our judgment the R merge in the shells above this cutoff was too high for these data to be included. The statistics of the data processing are shown in Table 1.

Table 1. Data-collection and reduction statistics.

Values in parentheses are for the highest resolution shell.

Space group P222
Unit-cell parameters (Å) a = 44.27, b = 68.39, c = 81.54
Wavelength (Å) 0.91940
Resolution limits (Å) 50.0–2.30 (2.38–2.30)
No. of observed reflections 57523
Unique reflections 11621
Completeness (%) 98.1 (99.6)
I/σ(I)〉 15.0 (2.6)
R merge (%) 11.5 (49.1)
Multiplicity 5.0 (4.3)

R merge = Inline graphic Inline graphic, where I i(hkl) is the intensity of the ith observation of an individual reflection hkl and 〈I(hkl)〉 is the average intensity for this reflection.

2.4. Enzymatic assays  

The enzymatic activity of AhV_aPA was detected according to the conventional method, using egg-yolk phospholipids as the substrate (Joubert & Taljaard, 1980). One egg yolk was suspended in 1 l physiological saline. 0.2 ml of this suspension was mixed with 0.8 ml 0.1 M Tris pH 8.0 with subsequent addition of 0.1 mg enzyme and was then incubated at 303 K. One unit of PLA2 activity was defined as the amount of protein which produced a decrease of 0.01 in the absorbance between 5 and 10 min at 740 nm. The specific activity was expressed as units per milligram of protein.

2.5. Isolation of thoracic aorta and tension measurement  

All animal experiments were conducted in accordance with NIH publication No. 8523. Isolated thoracic aortic strip segments for tension measurements were prepared as described previously (Ye et al., 2004). Briefly, five-week male ICR mice were killed using CO2 gas. The thoracic aorta was then rapidly dissected free and placed in Krebs–Henseleit solution (58 mM NaCl, 64.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4.7H2O, 25.2 mM NaHCO3, 11.1 mM glucose). At room temperature (298 K), the adhering perivascular tissue was carefully removed and the descending thoracic aorta was cut into 2 mm rings. The vessels were mounted onto two thin stainless steel holders in 0.5 ml organ baths containing Krebs–Henseleit solution at 310 K and continuously bubbled with a gas mixture consisting of 95% O2 and 5% CO2 to maintain a pH of 7.4. 500–550mg passive tension was applied to the vessel to produce the optimal resting tension. After an equilibration period of 1 h, the vessel was contracted twice using 60 mM K+ solution (58 mM NaCl, 64.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4.7H2O, 25.2 mM NaHCO3, 11.1 mM glucose). After a subsequent wash, the vessels were again preconstricted with 60 mM K+ solution in order to achieve sustained contractions. AhV_aPA was then added in a cumulative fashion to the bath to obtain the concentration-response curve. The contractile response to AhV_aPA was expressed as a percentage of the 60 mM K+-induced tone.

AhV_aPA stock solutions were prepared in deionized water and stored at 253 K in small aliquots for not more than one week. The isometric tension was recorded on a polygraph (BL-420 System, BL-NewCentury, TME Technology, People’s Republic of China).

2.6. Statistical analysis  

The results of the enzymatic assays and tension measurements were expressed as mean ± standard deviation. In the concentration-response curves, the data were fitted to the sigmoidal dose-response equation with variable Hill slope {y = bottom + (top − bottom)/[1 + Inline graphic], where C is the logarithm of the AhV_aPA concentration} using Origin software (http://www.originlab.com/).

3. Results and discussion  

In the present work, AhV_aPA was isolated from A. halys pallas venom using a three-step chromatographic procedure (Fig. 1). The electrophoretic profile of AhV_aPA obtained by SDS–PAGE showed a single band of ∼14 kDa under nonreducing conditions (Fig. 1 c). The purified enzyme efficiently cleaved egg-yolk phospholipids with a specific enzymatic activity of 6.2 ± 0.2 × 104 U mg−1 (four independent measurements).

We examined the effects of AhV_aPA on mouse thoracic aortic ring contraction. The studies remarkably showed that AhV_aPA could induce a further contractile response on the 60 mM K+-induced contraction (Fig. 3 a). The concentration-response curves were fitted to the sigmoidal dose-response equation and the obtained EC50 and Hill slope were 369 nmol l−1 and 2.43, respectively (six rings from six mice; Fig. 3 b). 500 nmol l−1 AhV_aPA induced a further contractile response of 21.1 ± 2.1% on the 60 mM K+ solution-induced contraction (eight rings from eight mice). Vascular tone is regulated by the channels in the plasma membrane of the vascular smooth-muscle cells, such as K+ channels, voltage-gated Ca2+ channels, store-operated Ca2+ (SOC) channels and stretch-activated cation (SAC) channels. Calcium influx through voltage-gated Ca2+, SOC and SAC channels provides the major source of activator Ca2+ used by resistance arteries and arterioles. In addition, Ca2+ release from the sarcoplasmatic reticulum (SR) and endoplasmic reticulum (ER) is involved in excitation–contraction coupling (Jackson, 2000). Natrin, a cysteine-rich secretory protein from N. atra venom, can specifically inhibit 60 mM K+-induced contraction in isolated thoracic aorta by blocking the BKca channels (Wang et al., 2005). Therefore, it is hypothesized that AhV_aPA may have effects on the ion channels or receptors in the plasma membrane of vascular smooth-muscle cells.

Figure 3.

Figure 3

Vasoconstrictor effect of AhV_aPA on mouse thoracic aortic strings. (a) Contractile response induced by 500 nmol l−1 AhV_aPA on 60 mM K+-induced contraction. (b) Concentration-response curve.

AhV_aPA crystallized in space group P222, with unit-cell parameters a = 44.27, b = 68.39, c = 81.54 Å. Calculations based on the protein molecular mass indicated the presence of two molecules in the asymmetric unit. This corresponds to a Matthews coefficient of 2.2 Å3 Da−1, with an approximate solvent content of 44%. Using the structure of an acidic PLA2 from Deinagkistrodon acutus venom (PDB entry 1ijl; 80% sequence identity; Gu et al., 2002) as a search model, the phase problem was solved by molecular replacement with MOLREP (the resolution range was 33.8–2.5 Å and the R factor and correlation coefficient reported by MOLREP were 47.8% and 0.56, respectively; Vagin & Teplyakov, 2010). REFMAC5 (Murshudov et al., 2011) was used for rigid-body refinement of this solution in the resolution range 40.0–2.3 Å (excluding the 5% of reflections used for R free calculation), resulting in an R factor of 38.7% and an R free of 41.6%. Structure refinement and analysis are currently in progress. It is expected that our crystal structure will help us to understand the significant/relevant differences between these PLA2 enzymes.

In conclusion, AhV_aPA isolated from A. halys pallas venom was crystallized and X-ray diffraction data were collected to 2.3 Å resolution. AhV_aPA has a high enzymatic activity, similar to other acidic aPLA2s. Like the natrin toxin from N. atra venom (Wang et al., 2005), AhV_aPA was identified to have vasoconstrictor activity on mouse thoracic aortic rings. Further structural studies, including a structural comparison with other PLA2s, may provide insights into the molecular basis of its biological actions.

Acknowledgments

We are grateful to the staff members at SSRF for the collection of diffraction data. Financial support for this project was provided by the Fundamental Research Funds for the Central Universities, the Chinese National Natural Science Foundation (grant Nos. 30900224 and 10979039), the Chinese Ministry of Science and Technology (grant Nos. 2006AA02A318 and 2009CB825500), the Science and Technological Fund of Anhui Province for Outstanding Youth (grant No. 10040606Y11), the Anhui Provincial Natural Science Foundation (grant No. 090413081) and the Education Department of Anhui Province (grant No. 2009SQRZ007ZD).

References

  1. dos Santos, J. I., Cintra-Francischinelli, M., Borges, R. J., Fernandes, C. A. H., Pizzo, P., Cintra, A. C. O., Braz, A. S. K., Soares, A. M. & Fontes, M. R. M. (2011). Proteins, 79, 61–78. [DOI] [PubMed]
  2. Duncan, R. E., Sarkadi-Nagy, E., Jaworski, K., Ahmadian, M. & Sul, H. S. (2008). J. Biol. Chem. 283, 25428–25436. [DOI] [PMC free article] [PubMed]
  3. Fernández, J., Gutiérrez, J. M., Angulo, Y., Sanz, L., Juárez, P., Calvete, J. J. & Lomonte, B. (2010). Biochimie, 92, 273–283. [DOI] [PubMed]
  4. Fuly, A. L., Calil-Elias, S., Zingali, R. B., Guimarães, J. A. & Melo, P. A. (2000). Toxicon, 38, 961–972. [DOI] [PubMed]
  5. Gu, L., Zhang, H., Song, S., Zhou, Y. & Lin, Z. (2002). Acta Cryst. D58, 104–110. [DOI] [PubMed]
  6. Hu, P., Sun, L., Zhu, Z.-Q., Hou, X.-W., Wang, S., Yu, S.-S., Wang, H.-L., Zhang, P., Wang, M., Niu, L. W., Teng, M.-K. & Ruan, D.-Y. (2008). Proteins, 72, 673–683. [DOI] [PubMed]
  7. Jackson, W. F. (2000). Hypertension, 35, 173–178. [DOI] [PMC free article] [PubMed]
  8. Joubert, F. J. & Taljaard, N. (1980). Eur. J. Biochem. 112, 493–499. [DOI] [PubMed]
  9. Kini, R. M. (2003). Toxicon, 42, 827–840. [DOI] [PubMed]
  10. Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. [DOI] [PMC free article] [PubMed]
  11. Nunes, D. C. O., Rodrigues, R. S., Lucena, M. N., Cologna, C. T., Oliveira, A. C. S., Hamaguchi, A., Homsi-Brandeburgo, M. I., Arantes, E. C., Teixeira, D. N. S., Ueira-Vieira, C. & Rodrigues, V. M. (2011). Comp. Biochem. Physiol. C Toxicol. Pharmacol. 154, 226–233. [DOI] [PubMed]
  12. Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. [DOI] [PubMed]
  13. Ponce-Soto, L. A., Barros, J. C., Marangoni, S., Hernandez, S., Dal Belo, C. A., Corrado, A. P., Hyslop, S. & Rodrigues-Simioni, L. (2009). Comp. Biochem. Physiol. C Toxicol. Pharmacol. 150, 291–297. [DOI] [PubMed]
  14. Saikia, D., Thakur, R. & Mukherjee, A. K. (2011). Toxicon, 57, 841–850. [DOI] [PubMed]
  15. Teixeira, S. S., Silveira, L. B., da Silva, F. M. N., Marchi-Salvador, D. P., Silva, F. P., Izidoro, L. F. M., Fuly, A. L., Juliano, M. A., dos Santos, C. R., Murakami, M. T., Sampaio, S. V., da Silva, S. L. & Soares, A. M. (2011). Arch. Toxicol. 85, 1219–1233. [DOI] [PubMed]
  16. Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25. [DOI] [PubMed]
  17. Wang, J., Shen, B., Guo, M., Lou, X., Duan, Y., Cheng, X. P., Teng, M., Niu, L., Liu, Q., Huang, Q. & Hao, Q. (2005). Biochemistry, 44, 10145–10152. [DOI] [PubMed]
  18. Ye, C., Shen, B., Ren, X., Luo, R., Ding, S., Yan, F. & Jiang, J. (2004). Acta Pharmacol. Sin. 25, 744–750. [PubMed]

Articles from Acta Crystallographica Section F: Structural Biology and Crystallization Communications are provided here courtesy of International Union of Crystallography

RESOURCES